Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non- ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia

Bintoro, Siprianus Ugroseno Yudho; Dwijayanti, Ni Made Intan; Pramudya, Dana; Amrita, Putu Niken Ayu; Romadhon, Pradana Zaky; Asmarawati, Tri Pudy; Bachtiar, Arief; Hadi, Usman

doi:10.12688/f1000research.53803.2

Cited by 2 publications

(1 citation statement)

References 29 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the overwhelming number of cases and the significant morbidity and mortality associated with SARS-CoV-2, reliable prognostic scores are critically important to maximize survivorship and optimize the use of limited resources. Sophisticated scoring systems have been proposed but have not performed consistently [4][5][6][7] . For example, El-Solh 4 tested 4 prognostic models constructed to predict in-hospital mortality for SARS-CoV-2 patients; proposed by Chen et al 8 , Shang et al 9 , Yu et al 10 , and Wang et al 11 .…”

Section: Summary Boxmentioning

confidence: 99%

Mapping of biomarker efficacy in SARS-CoV-2: tracking the impact of viral mutations and vaccinations

Shuvo

Schwiening

Soares

et al. 2022

Preprint

View full text Add to dashboard Cite

Objectives: Sophisticated scores have been proposed for prognostication of mortality due to SARS-CoV-2 but perform inconsistently. We conducted these meta-analyses to uncover why and to pragmatically seek a single dependable biomarker for mortality. Design: We searched the PubMed database for the keywords SARS-CoV-2 with biomarker name and mortality. All studies published from 01st December 2019 to 30th June 2021 were surveyed. To aggregate the data, the meta library in R was used to report overall mean values and 95% confidence intervals. We fitted a random effects model to obtain pooled AUCs and associated 95% confidence intervals for the European/North American, Asian, and overall datasets. Setting and Participants: Data was collected from 131 studies on SARS-CoV-2 PCR-positive general hospital adult admissions (n=76,169 patients in total). Main Outcome Measures: We planned a comparison of pooled area under curves (AUCs) from Receiver Operator Characteristic curves plotted for admission D-dimer, CRP, urea, troponin and interleukin-6 levels. Main Results: Biomarker effectiveness varies significantly in different regions of the world. Admission CRP levels are a good prognostic marker for mortality due to SARS-CoV-2 in Asian countries, with a pooled area under curve (AUC) of 0.83 (95% CI 0.80-0.85), but only an average predictor of mortality in Europe/North America, with a pooled AUC of 0.67 (95% CI 0.63-0.71, P<0.0001). We observed the same pattern for D-dimer and IL-6. This variability explains why the proposed prognostic scores did not perform evenly. Notably, urea and troponin had pooled AUCs ≥ 0.78 regardless of location, implying that end-organ damage at presentation is a key prognostic factor. These differences might be due to age, genetic backgrounds, or different modes of death (younger patients in Asia dying of cytokine storm while older patients die of multi-organ failure). Conclusions: Biomarker effectiveness for prognosticating SARS-CoV-2 mortality varies significantly by geographical location. We propose that biomarkers and by extension prognostic scores need to be tailored for specific populations. This also implies that validation of commonly used prognostic scores for other conditions should occur before they are used in different populations.

show abstract

Section: Summary Boxmentioning

confidence: 99%

Mapping of biomarker efficacy in SARS-CoV-2: tracking the impact of viral mutations and vaccinations

Shuvo

Schwiening

Soares

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus

et al. 2022

View full text Add to dashboard Cite

The clinical symptoms of COVID-19 infection differ from one patient to another, requiring different management. This study intended to characterize the clinical manifestation of COVID-19 in patients with asthma, hypertension, and diabetes mellitus (DM). We analyzed data from 540 medical records of patients with comorbidities like asthma, hypertension, and DM diagnosed with COVID-19, looking at vital signs upon admission, chest X-ray, and laboratory results. Most patients were male (57.0%). The most prevalent comorbidity was hypertension (46.3%) and DM (46.3%), followed by asthma (7.4%). 273 patients had improved condition (50.6%). Patients with hypertension had the most extended length of stay compared to other comorbidities groups (13.0±8.5 days). There were significant differences in the oxygen saturation and respiration rate between the three groups (p=0.002, p<0.0001, respectively). The mean lymphocyte (p=0.028) and hematocrit count (p=0.001) were significantly different between the three comorbid groups, with the hypertension group having the highest mean lymphocyte (15.1±8.9) and hematocrit (38.7±6.9) count. COVID-19 had a significant impact on patients with asthma, hypertension, and diabetes comorbidities concerning the final condition, length of stay, oxygen saturation, and respiratory rate, and also on the hematology level, mainly lymphocyte and hematocrit. Treatment, age, and infection might be determinant factors for different outcomes in each type of comorbidity.

show abstract

Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non- ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia

Cited by 2 publications

References 29 publications

Mapping of biomarker efficacy in SARS-CoV-2: tracking the impact of viral mutations and vaccinations

Mapping of biomarker efficacy in SARS-CoV-2: tracking the impact of viral mutations and vaccinations

Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus

Contact Info

Product

Resources

About